The Muttenz based INOFEA focused on the development of a novel enzyme platform, has concluded a purchase and supply agreement with UCB, a global biopharmaceutical company with 4,9 billion in revenues (2019). The companies plan a long-term collaboration in the field of stabilized enzymes used for the clinical development of new drugs.
Founded in 2014, INOFEA developed the enzzen technology platform, which anchors enzymes to particles and protects them by applying a structured coating. The platform can be applied across different industries for instance in the pharmaceutical and food industries to produce medicines and infant food more efficiently and safely, and in the chemical industry and consumer care.
Phase of expansion
INOFEA has attracted various customers from some of the largest pharmaceutical and food companies in the world. In 2019, the company signed a development contract with a leading food company and launched a pilot study with an international pharmaceutical group thereafter. Other clients include small and medium-sized companies that want to use stabilised enzymes. Due to the numerous requests from Swiss and international industry, INOFEA is currently in a phase of expansion.
Building on their success, INOFEA has signed a purchase and supply agreement with the UCB, a Brussel-based pharmaceutical company developing a pipeline of drugs to treat patients with severe diseases in neurology and immunology. The company achieved revenues of € 4.9 billion in 2019. Thanks to the partnership, INOFEA has won a long-term partner in the field of stabilized enzymes used for the clinical development of new drugs.
(Press release / RAN)
Please login or sign up to comment.
Commenting guidelines